Augmedix, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Loss Per Share

Loss Per Share

12 Months Ended

Dec. 31, 2023

Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of common stock outstanding during each period. Diluted net loss per common stock includes the effect, if any, from the potential exercise or conversion of securities, such as options and warrants which would result in the issuance of incremental common stock. In computing basic and diluted net loss per share, the weighted average number of shares is the same for both calculations due to the fact that a net loss existed for the years ended December 31, 2023 and 2022.

The Company calculated basic and diluted net loss per share as follows:


	Year Ended December 31,
	2023		2022
Numerator
Net Loss	$	(19,171)	$	(24,449)

Denominator
Weighted average shares, basic and diluted	43,946,263		37,418,463

Net loss per share	$	(0.44)	$	(0.65)

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:


	December 31,
	2023	2022
Common stock warrants	4,372,757	2,801,703
Stock options	9,342,589	8,234,823
Restricted stock units	303,688	263,155
	14,019,034	11,299,681